Partners to your ideas
Creating Value through Partnerships
As of today, more than half of our development portfolio consisted of projects originated by external R&D and about one third of Sanofi pharma 2011 net sales came from products developed through alliances or partnerships.
Sanofi top management has decided to go further and to dedicate significant amount of its time to explore new business opportunities. This strong commitment of Sanofi top management is supported by teams fully dedicated to create value at all levels: Business Development, R&D, Commercial, Industrial Affairs…
Sanofi continued to pursue its strategy of targeted acquisitions and R&D partnerships, with:
- The acquisition of Genzyme in April 2011.
- In Consumer Health Care, the Group successfully completed its acquisition of BMP Sunstone in China.
- In Animal Health, Merial became Sanofi’s dedicated animal health division following the joint statement issued by Merck and Sanofi in March 2011 announcing the end of their agreement to create a new animal health joint venture by combining their respective animal health activities.
In addition, partnership and licensing agreements have enabled the Group to expand and to further develop its existing areas of research.
Furthermore, Sanofi benefiting from a strong financial profile, with one of the highest credit rating of the pharmaceutical industry has a strong flexibility to quickly commit its financial resources to the right projects.
Vice President Corporate Licenses
Vice President, Mergers and Acquisitions
Partnering press releases
March 25, 2013